Efficacy and Safety Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Proxalutamide (GT0918) in adult outpatients diagnosed with mild to moderate COVID-19. The study will be 2-arm comparison against matched placebo. The study will be conducted in around 100 sites in the USA and other countries. This study utilizes an adaptive design that maximizes our efficiency in identifying a safe and efficacious therapeutic agent for COVID-19 during the current outbreak. There will be an interim analysis after 334 subjects complete Day 28 after the first dose to allow early stopping for futility, efficacy, or safety. The study population will be subjects with mild to moderate COVID-19 illness chosen to evaluate if early intervention with anti-androgen therapy prior to respiratory compromise can effectively prevent progression to the severe form of COVID-19 illness. Randomization is essential for establishing efficacy of these new therapeutic agents. The blood samples for PK analysis need to be collected for at least 200 subjects, whom will also be randomized into the interventional treatment or placebo group with 1:1 ratio. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04759534 -
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
Not yet recruiting |
NCT05532111 -
Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial
|
N/A | |
Active, not recruiting |
NCT04284215 -
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC
|
N/A | |
Completed |
NCT06202456 -
A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver
|
Phase 4 | |
Completed |
NCT03660761 -
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03794778 -
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
|
Phase 4 | |
Recruiting |
NCT03255343 -
Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim
|
N/A | |
Recruiting |
NCT04197544 -
Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.
|
N/A | |
Recruiting |
NCT04518501 -
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03779776 -
The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants
|
N/A | |
Not yet recruiting |
NCT06218004 -
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT02809079 -
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
|
Phase 4 | |
Active, not recruiting |
NCT06194188 -
A Phase 2 Clinical Study of CU-20401
|
Phase 2 | |
Recruiting |
NCT03901235 -
MSC Intratissular Injection in Crohn Disease Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03826004 -
Clemastine in Cardiovascular Surgery
|
N/A | |
Active, not recruiting |
NCT03623776 -
Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.
|
Phase 2 | |
Recruiting |
NCT04078399 -
Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence
|
N/A | |
Not yet recruiting |
NCT06351735 -
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
|
||
Not yet recruiting |
NCT06383078 -
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
|
Phase 2 | |
Withdrawn |
NCT05481775 -
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
|
Phase 2 |